Jazz Pharmaceuticals JAZZ Non-deductible financing costs
Non-deductible financing costs at other companies
Other financials
Where this comes from
Reported directly by Jazz Pharmaceuticals in its filing.
Tagged under the XBRL concept jazz:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseFinancingCostsAmount.
The official record: Jazz Pharmaceuticals’s 10-K, filed February 24, 2026, on SEC EDGAR. View the filing →
Ask your AI about Jazz Pharmaceuticals's non-deductible financing costs.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Jazz Pharmaceuticals's non-deductible financing costs?
- Jazz Pharmaceuticals (JAZZ) reported non-deductible financing costs of $5.61M in Q4 2024.
- How has Jazz Pharmaceuticals's non-deductible financing costs changed year-over-year?
- Jazz Pharmaceuticals's non-deductible financing costs increased by 42.9% year-over-year, from $3.93M to $5.61M.
- What is the long-term trend for Jazz Pharmaceuticals's non-deductible financing costs?
- Over 3 years (2021 to 2024), Jazz Pharmaceuticals's non-deductible financing costs has grown at a 15.9% compound annual growth rate (CAGR), from $14.42M to $22.44M.
- What does non-deductible financing costs mean?
- Financing costs that cannot be deducted to reduce taxable income.
- How do you interpret non-deductible financing costs?
- Higher amounts indicate less efficient capital structures from a tax perspective, increasing the effective tax rate.
- How does non-deductible financing costs compare across companies?
- Commonly found in tax reconciliation tables for companies with complex debt or equity financing.